Stereoselective synthesis of an anti-HIV drug candidate

Chirality

Volumn 17, Issue SUPPL., 2005, Pages

  Conlon, David A ^a   Jensen, Mark S ^a   Palucki, Michael ^a   Yasuda, Nobuyoshi ^a   Um, Joann M ^a   Yang, Chunhua ^a   Hartner, Frederick W ^a   Tsay, Fuh Rong ^a   Hsiao, Yi ^a   Pye, Philip ^a   Rivera, Nelo R ^a   Hughes, David L ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Allylic alkylation; Asymmetric catalysis; Enantiomeric purity; Enantioselectivity

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CYCLOPENTANE; MOLYBDENUM; OXAZOLIDINONE DERIVATIVE; PYRAZOLE;

ALKYLATION; CATALYSIS; CONFERENCE PAPER; DIASTEREOISOMER; DIELS ALDER REACTION; DRUG SYNTHESIS; PRIORITY JOURNAL; STEREOCHEMISTRY;

EID: 21844444522     PISSN: 08990042     EISSN: None     Source Type: Journal    
DOI: 10.1002/chir.20137     Document Type: Conference Paper

References (27)

1. Kilby JM, Eron JJ. Novel therapies based on mechanisms of HIV-1 cell entry. N Engl J Med 2003;348:2228-2238.
2. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, Saragosti S, Lapouméroulie C, Cognaux J, Forceille C, Muyldermans G, Verhofstede C, Burtonboy G, Georges M, Imai T, Rana S, Yi Y, Smyth RJ, Collman RG, Doms RW, Vassart G, Parmentier M. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996;382: 722-725.
3. Ono SJ, Nakamura T, Miyazaki D, Ohbayashi M, Dawson M, Toda M. Chemokines: roles in leukocyte development, trafficking, and effector function. J Allergy Clin Immunol 2003;111:1185-1199.
4. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, MacDonald ME, Stuhlmann H, Koup RA, Landau NR. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996;86:367-377.
5. (a) Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath PD, Wu L, Mackay CR, LaRosa G, Newman W, Gerard N, Gerard C, Sodroski J. The β-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996;85:1135-1148.
6. (b) Doranz BJ, Rucker J, Yi Y, Smyth RJ, Samson M, Peiper SC, Parmentier M, Collman RG, Doms RW. A dual-tropic primary HIV-1 isolate that uses fusin and the β-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 1996;85:1149-1158.
7. + cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996;381: 667-673.
8. (d) Deng HK, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, Landau NR. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996;381: 661-666.
9. (e) Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, Berger E-A. CC CKR5: a RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996;272:1955-1958.
10. (a) Kazmierski W, Bifulco N, Yang H, Boone L, DeAnda F, Watson C, Kenakin T. Recent progress in discovery of small-molecule CCR5 chemokine receptor ligands as HIV-1 inhibitors. Bioorg Med Chem 2003;11:2663-2676.
11. (b) Simmons G, Clapham PR, Picard L, Offord RE, Rosenkilde MM, Schwartz TW, Buser R, Wells TNC, Proudfoot AEl. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 1997;276:276-279.
12. (c) Hale JJ, Budhu RJ, Mills SG, MacCoss M, Malkowitz L, Siciliano S, Gould SL, DeMartino JA, Springer MS. 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 1: discovery of the pyrrolidine scaffold and determination of its stereochemical requirements. Bioorg Med Chem Lett 2001;11:1437-1440.
13. (d) Hale JJ, Budhu RJ, Holson EB, Finke PE, Gates B, Mills SG, MacCoss M, Gould SL, DeMartino JA, Springer MS, Siciliano S, Malkowitz L, Schleif WA, Huzuda D, Miller M, Kessler J, Danzeisen R, Holmes K, Lineberger J, Carella A, Carver G, Emini E. 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 2: lead optimization affording selective, orally bioavailable compounds with potent Anti-HIV activity. Bioorg Med Chem Lett 2001;11:2741-2745.
14. (e) Tsamis F, Gavrilov S, Kajumo F, Seibert C, Kuhmann S, Ketas T, Trkola A, Palani A, Clader JW, Tagat JR, McCombie S, Baroudy B, Moore JP, Sakmar TP, Dragic T. Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-3505S1 inhibit human immunodeficiency virus type 1 entry. J Virol 2003;77:5201-5208.
15. (f) Chen X, Yang L, Zhang N, Turpin JA, Buckheit RW, Osterling C, Oppenheim JJ, Howard OMZ. Shikonin, a component of Chinese herbal medicine, inhibits chemokine receptor function and suppresses human immunodeficiency virus type 1. Antimicrob Agents Chemother 2003;47: 2810-2816.
16. Finke PE, Hilfiker KA, MacCoss M, Chapman KT, Loebach JL, Mills SG, Guthikonda RN, Shah SK, Kim D, Shen DM, Oates B. N-Cyclopentyl modulators of chemokine receptor activity. U.S. Patents 6,358,979, March 19, 2002, and 6,593,346, July 15, 2003.
17. For a review on [3+2] cycloaddition approaches to five-membered rings using trimethylenemethane chemistry, see: Trost BM. [3+2] Cycloaddition approaches to five-membered rings via trimethylene-methane and its equivalents. Angew Chem Int Ed Engl 1986;25:1-114.
18. Palucki M, Um JM, Yasuda N, Conlon DA, Tsay FR, Hartner FW, Hsiao Y, Marcune B, Karady S, Hughes DL, Dormer PG, Reider PJ. Development of a new and practical route to chiral 3,4-disubstituted cyclopentanones: asymmetric alkylation and intramolecular cyclopropanation as key C-C bond-forming steps. J Org Chem 2002;67: 5508-5516.
19. Organ MG, Murray AP. Ni-catalyzed cross coupling of alkoxide-containing vinyl halides with Grignard reagents. A "one-pot" synthesis of 2-[(trimethylsilyl)methyl]-2-propen-l-yl acetate. J Org Chem 1997; 62:1523-1526.
20. Taschner MJ. Asymmetric Diels-Alder reactions. Greenwich, CT: JAI Press, Inc.; 1989. Vol 1, p 1-101.
21. (a) Boeckman Jr RK, Naegely PC, Arthur SD. Efficient enantioselective synthesis of the antitumor agent sarkomycin. J Org Chem 1980;45:752-754.
22. (b) Boeckman Jr RK, Napier JJ, Thomas EW, Sato RI. Stereocontrol in the intramolecular Diels-Alder reaction. 5. Preparation of a tetracyclic intermediate for ikarugamycin. J Org Chem 1983;48:4152-4154.
23. White WL, Anzeveno PB, Johnson F. Prostaglandins. 3. Synthetic approaches to 11-deoxyprostaglandins. J Org Chem 1982;47:2379-2387.
24. Abdel-Magid AF, Carson KG, Harris BD, Maryanofi CA, Shah RD. Reductive amination of aldehydes and ketones with sodium triacetoxyborohydride. Studies on direct and indirect reductive amination procedures. J Org Chem 1996;61:3849-3862.
25. Evans DA, Chapman KT, Carreira EM. Directed reduction of β-hydroxy ketones employing tetramethylammonium triacetoxyborohydride. J Am Chem Soc 1988;110:3560-3578.
26. Shen DM, Shu M, Mills SG, Chapman KT, Malkowitz L, Springer MS, Gould SL, DeMartino JA, Siciliano SJ, Kwei GY, Carella A, Carver G, Holmes K, Schleif WA, Danzeisen R, Hazuda D, Kessler J, Lineberger J, Miller MD, Emini EA. Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 1: discovery and SAR study of 4-pyrazolylpiperidine side chains. Bioorg Med Chem Lett 2004;14:935-939.
27. Mills JE, Maryanoff CA, McComsey DF, Stanzione RC, Scott L. The reaction of amines with methylene chloride. Evidence for rapid aminal formation from N-methylenepurrolidinium chloride and pyrrolidine. J Org Chem 1987;52:1857-1859.